<?xml version="1.0" encoding="UTF-8"?>
<ref id="ref168">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Zenilman</surname>
    <given-names>J. M.</given-names>
   </name>
   <name>
    <surname>Fuchs</surname>
    <given-names>E. J.</given-names>
   </name>
   <name>
    <surname>Hendrix</surname>
    <given-names>C. W.</given-names>
   </name>
   <name>
    <surname>Radebaugh</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Jurao</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Nayak</surname>
    <given-names>S. U.</given-names>
   </name>
   <etal/>
  </person-group>. (
  <year>2015</year>). 
  <article-title>Phase 1 clinical trials of DAS181, an inhaled sialidase, in healthy adults</article-title>. 
  <source>Antiviral Res.</source>
  <volume>123</volume>, 
  <fpage>114</fpage>â€“
  <lpage>119</lpage>. 
  <pub-id pub-id-type="doi">10.1016/j.antiviral.2015.09.008</pub-id>, PMID: 
  <?supplied-pmid 26391974?>
  <pub-id pub-id-type="pmid">26391974</pub-id>
 </mixed-citation>
</ref>
